|
|
|
|
||
Patent! What patent?"Jefferies analyst Akash Tewari initiated coverage of Exelixis with a Buy rating and $28 price target. The analyst said that, despite recent clinical setbacks, Exelixis is one of the "most interesting" IP plays in SMID cap heading into next year. Tewari is bullish on Cabometyx's polymorph IP going out to 2030, which could add 30% to the stock, he said." |
return to message board, top of board |